ATAC Research Fund at TGen

The ATAC Research project at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona,was founded by Troy Richards, a three time, 9 year Adrenal Cancer survivor. With the goal of having research dedicated only to Adrenocortical Carcinoma (ACC), the ATAC Fund is now one of the largest ACC research projects in the world, already discovering hopeful new targets, producing more ACC data than ever before and using tools never before used on ACC research. Adrenocortical Carcinoma (ACC) is a rare cancer of the adrenal cortex, the outside layer of the adrenal glands which are located above each kidney. Tumors of the adrenal cortex may overproduce hormones, which cause symptoms such as high blood pressure, weight gain, or diabetes.

TGen is currently leading one of the largest Genomics ACC research project to date. There is only one drug on the market approved for the disease. In the past 40 years, little progress has been made toward finding an effective treatments for ACC. It strikes only one or two people in a million and is often difficult to collect enough tumor samples to analyze, which is why the TGen study is so significant. The research program at TGen, headed by and Michael Demeure, M.D. and Kimberly Bussey, Ph.D., is currently analyzing ACC tumors, benign adrenal tumors, and normal tissue with several Genomics technologies. TGen researchers are using the Genomics data to identify mutations and design new diagnostic tools and therapeutics to combat this aggressive cancer.

DISCLAIMER

The intention of this web site is to give information and attention to a rare cancer. The information provided here is not intended, nor should it be construed, as a substitute for professional medical advice. Some of these documents contain copyrighted material whose use has not been specifically authorized by the copyright owners.